BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LEN
8. USO
9. LMT
10. TLT

Go back to BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jones Trading Reiterates Hold Rating on BioLineRx (BLRX)

May 28, 2025 8:59 AM EDT

Jones Trading analyst Justin Walsh reiterated a Hold rating on BioLineRx (NASDAQ: BLRX).

The analyst comments "APHEXDA will provide a steady stream of royalties that support earlier stage development of assets expected to be in-licensed in 2025-2026, most likely in the oncology and/or... More